GlassScriptPhysician profile
Qin Ouyang
NPI 1295024727
$2,463.23
in general payments reported to CMS, 2019-2025
12 companies · $589 in 2025
The $589 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $565 · 2020: $122 · 2023: $719 · 2024: $468 · 2025: $589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,712 · Long Term Medical Supply Or Device Loan: $49.95 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,712.43 |
| Long Term Medical Supply Or Device Loan | $49.95 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $562.39 | 2019-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Medtronic, INC. | $384.05 | 2023-2025 | Minimed 780g |
| Tandem Diabetes Care, INC. | $308.61 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $247.35 | 2019-2025 | |
| Beta Bionics, INC. | $219.21 | 2023-2024 | Ilet Bionic Pancreas |
| Abbott Laboratories | $202.06 | 2024-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Novo Nordisk INC | $124.99 | 2025 | Ozempic |
| Horizon Therapeutics Plc | $123.05 | 2023 | Tepezza |
| Stemline Therapeutics INC. | $103.02 | 2023 | Orserdu |
| Nevro Corp. | $102.96 | 2019 | |
| Insulet Corporation | $74.17 | 2023 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Qin Ouyang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.